Matsumoto Toshihiko, Cho Sien, Nakasya Akio, Nagai Hiroki, Satake Hironaga, Yasui Hisateru
Department of Medical Oncology, Ichinoimiya Nishi Hospital, 1, Kaimei Aza Hira, Ichinomiya City, Aichi, 4940001, Japan.
Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe City, Hyogo, Japan.
Sci Rep. 2024 Dec 3;14(1):30017. doi: 10.1038/s41598-024-81195-3.
To report the efficacy of anamorelin in patients with colorectal and gastric cancer with cachexia and in those receiving systemic chemotherapy. We retrospectively collected real-world data from patients diagnosed with colorectal and gastric cancers experiencing cachexia who were treated with anamorelin. We evaluated the efficacy of treatment by measuring the improvements in appetite and body weight (BW) gain. Between June 2021 and October 2022, 43 cancer patients with cachexia-23 with gastric cancer and 20 with colorectal cancer-were treated with anamorelin. Median observation period was 7.3 months. The participants were 25 males with median age of 71 years and median BMI of 19.7. The ECOG PS distribution was 4, 33, 6 for grades 0, 1, and 2, respectively. Seven patients received supportive care only, while 36 received anamorelin with chemotherapy. Thirty-four had received chemotherapy previously (≤ 2 regimens) and nine had received ≥ 3 regimens. Median anamorelin treatment duration was 2.8 months; overall survival was 7.3 months. After 3 weeks, 24 experienced appetite improvement and 21 gained weight; after 12 weeks, 20 experienced appetite improvement and 15 gained weight. Multivariate analysis showed that anamorelin treatment before second-line chemotherapy and colorectal cancer correlated with appetite improvement and weight gain at 3 weeks. In the univariate analysis, anamorelin treatment before second-line chemotherapy correlated with weight gain at 12 weeks and with improved overall survival in patients with weight gain at 12 weeks. Early anamorelin treatment contributes to appetite improvement and BW gain in colorectal and gastric cancers with cachexia.
报告阿那莫林对患有恶病质的结直肠癌和胃癌患者以及接受全身化疗患者的疗效。我们回顾性收集了诊断为患有恶病质的结直肠癌和胃癌且接受阿那莫林治疗患者的真实世界数据。我们通过测量食欲改善情况和体重增加来评估治疗效果。在2021年6月至2022年10月期间，43例患有恶病质的癌症患者（23例胃癌患者和20例结直肠癌患者）接受了阿那莫林治疗。中位观察期为7.3个月。参与者为25名男性，中位年龄为71岁，中位体重指数为19.7。东部肿瘤协作组（ECOG）体能状态分布中，0级、1级和2级分别为4例、33例和6例。7例患者仅接受支持性治疗，而36例患者接受阿那莫林联合化疗。34例患者之前接受过化疗（≤2个疗程），9例患者接受过≥3个疗程的化疗。阿那莫林中位治疗持续时间为2.8个月；总生存期为7.3个月。3周后，24例患者食欲改善，21例患者体重增加；12周后，20例患者食欲改善，15例患者体重增加。多变量分析显示，二线化疗前使用阿那莫林治疗以及结直肠癌与3周时的食欲改善和体重增加相关。在单变量分析中，二线化疗前使用阿那莫林治疗与12周时的体重增加以及12周时体重增加患者的总生存期改善相关。早期使用阿那莫林治疗有助于改善患有恶病质的结直肠癌和胃癌患者的食欲并增加体重。
